Suven to unveil new results, data presentations at AAIC

25 Jul 2016 Evaluate

Suven is exhibiting and presenting several exciting new results and data presentations from its portfolio of investigational neuroscience New Chemical Entities (NCEs) at Alzheimer's Association International Conference (AAIC) being held in Toronto, Canada during July 24th to 28th, 2016.  AAIC is the world's largest conference of its kind, where thousands of international investigators, clinicians, researchers and care providers will gather to share the latest study results, theories and discoveries bringing the world closer to breakthroughs in dementia science.

Alzheimer’s disease is one of the scourges of modern day health care. Alzheimer’s is not just a memory loss as everyone thinks but Alzheimer’s kills. Current Alzheimer's treatments cannot stop Alzheimer's from progressing, they can temporarily slow the worsening of dementia symptoms and improve quality of life. Today, there is a worldwide effort under way to find better ways to treat the disease, delay its onset, and prevent it from developing and this is where Suven is focusing in developing a drug for the treatment of this debilitating disease.

Suven has excellent portfolio of new molecules through four mechanisms of action using 5- HT6, 5-HT4, H3 and Neuronal Nicotinic acetylcholine receptors for the symptomatic treatment of cognitive impairment in Alzheimer’s disease but also possibly useful in reducing the disease progression. Suven scientists are presenting pre-clinical and clinical data on these molecule and other NCEs on memory related disorders and major depressive disorder.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. The company has 3 clinical stage compounds, a Phase 2 undergoing candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 undergoing candidate SUVN-D4010 for Alzheimer’s disease and Schizophrenia.

Suven Life Sciences Share Price

167.40 0.55 (0.33%)
01-Jan-2026 09:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.90
Dr. Reddys Lab 1252.85
Cipla 1502.95
Zydus Lifesciences 910.75
Lupin 2096.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×